Literature DB >> 18162083

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.

J R Pisegna1, M B Sostek, J T Monyak, P B Miner.   

Abstract

BACKGROUND: Intravenous (IV) formulations of proton pump inhibitors are effective for patients in whom oral therapy is not appropriate. AIM: To compare IV esomeprazole and IV lansoprazole for the control of intragastric pH.
METHODS: In this open-label crossover study, healthy, Helicobacter pylori-negative adults were randomized to one of two treatment sequences, each consisting of two 5-day dosing periods of IV esomeprazole 40 mg or IV lansoprazole 30 mg. Twenty-four-hour intragastric pH monitoring was conducted on days 1 and 5 of each dosing period.
RESULTS: On days 1 and 5, intragastric pH was >4.0 significantly longer with esomeprazole than lansoprazole (least-squares means: day 1, 40.0% vs. 33.6%; day 5, 61.9% vs. 45.4%; both P < 0.0001). During the first 4 h of pH monitoring, intragastric pH was >4.0 significantly longer on days 1 and 5 with esomeprazole than lansoprazole (P < 0.0001). Kaplan-Meier estimates of median hours to stable pH >4.0 were 4.92 for esomeprazole and 5.75 for lansoprazole (P = 0.0014 for test on Gehan scores).
CONCLUSION: In healthy adults, IV esomeprazole 40 mg controlled intragastric acidity faster and more effectively than IV lansoprazole 30 mg.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162083      PMCID: PMC6736538          DOI: 10.1111/j.1365-2036.2007.03592.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

Review 1.  Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disorders.

Authors:  Marc Bardou; Janet Martin; Alan Barkun
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.

Authors:  Xian-Bao Zhan; Xiao-Rong Guo; Zhao-Shen Li; Yan-Fang Gong; Jun Gao; Zhuan Liao; Zhen Li; Shen Gao; Pei Liu
Journal:  Med Sci Monit       Date:  2012-02

3.  Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.

Authors:  Tasuku Kuwayama; Hiroyuki Osanai; Masayoshi Ajioka; Kotaro Tokuda; Hirofumi Ohashi; Akihiro Tobe; Tatsuya Yoshida; Tomohiro Masutomi; Takahiro Kambara; Yosuke Inoue; Yoshihito Nakashima; Hiroshi Asano; Kazuyoshi Sakai
Journal:  J Arrhythm       Date:  2017-10-12

Review 4.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.